Radius Health, Inc.
950 Winter Street
Waltham, MA 02451
Phone: (617) 551 4000Website: https://radiuspharm.com/Careers: radiuspharm.com/careers
- Radius Health’s Tymlos (abaloparatide) Receives U.S. FDA Approval as a Treatment to Increase Bone Density in Men with Osteoporosis at High Risk for Fracture
20 December 2022
- Radius Announces Update on Tymlos (abaloparatide) Label
23 December 2021
- FDA Approves Tymlos (abaloparatide) for the Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture
28 April 2017
- Radius Health Receives Notification of PDUFA Extension for Abaloparatide-SC
10 March 2017
- Radius Announces FDA Acceptance for Filing of NDA for Abaloparatide-SC for the Treatment of Postmenopausal Women with Osteoporosis
31 May 2016
- Radius Health Submits NDA to the U.S. FDA for Abaloparatide-SC for the Treatment of Postmenopausal Women with Osteoporosis
30 March 2016
Drugs Associated with Radius Health, Inc.
Radius Health, Inc. manufactures, markets and/or distributes 1 drug in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.
Generic name: abaloparatide
Drug class: parathyroid hormone and analogs
|72 reviews||4.4 / 10|
|For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective).|